Trait: cognitive decline measurement

Experimental Factor Ontology (EFO) Information
Identifier EFO_0007710
Description
  • quantification of some aspect of cognitive decline such as the rate at which it occurs or its severity, for example in patients with dementia or Alzheimer's disease. Cognitive decline is ususally assessed using a structured-interview protocol covering a number of standardised areas.
Trait category
Other measurement

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution PGS Scoring File (FTP Link)
PGS000777
(PHS3_PDD)
PGP000181 |
Liu G et al. Nat Genet (2021)
Parkinsons disease dementia cognitive decline measurement,
Parkinson's disease
3
http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000777/ScoringFiles/PGS000777.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002014 PGS000777
(PHS3_PDD)
PSS000997|
Multi-ancestry (including European)|
404 individuals
PGP000181 |
Liu G et al. Nat Genet (2021)
Reported Trait: Parkinson's disease dementia HR: 2.05 [1.16, 3.61] AUROC: 0.688 [0.519, 0.817] Hazard's Ratio (HR, top 25% vs PHS of 0): 3.2 [1.26, 8.11] Age at Parkinson's disease onset, sex, years of education, PCs(1-10), study cohort, genetic factors (genes: GBA, APOE ε4)

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000997 All individuals had Parkinsons' disease. Dementia was defined by the following criteria for each cohort. DeNoPa: Dementia was defined using operationalized level 1 MDS dementia criteria. These criteria required 1, an MMSE< 26; 2, cognitive deficits severe enough to impact daily living (MDS-UPDRS sub-score I item 1, Cognitive impairment score ≥ 2 indicating ‘Dementia has impact on active daily living scale’); 3, impairment in at least two cognitive domains operationalized as impairment in two of the following four tasks: ≤ 3 of 5 points in the MMSE Seven backward test (attention); abnormal clock drawing test (executive dysfunction); subscore = 0 in the MMSE Pentagons (visuo-constructive ability); and ≤ 2 of 3 points in the 3-Word Recall of the MMSE (memory performance). A Geriatric Depression Scale-15 (GDS-15) score <10 was used to indicate the absence of severe depression. EPIPARK: Dementia was defined using operationalized level 1 MDS dementia criteria. These criteria required 1, a Montreal Cognitive Assessment (MoCA) score < 2127; 2, cognitive deficits severe enough to impact daily living (UPDRS sub-score I item 1, Intellectual impairment score ≥ 2 indicating ‘Dementia has impact on active daily living scale’); 3, impairment in at least two cognitive domains operationalized as impairment in two of the following four tasks: ≤ 2 of 3 points in the MoCA serial seven subtraction test; 0 points in the MoCA language fluency test item (language); ≤ 4 of 5 points in the word recall of the MoCA (delayed recall); ≤ 4 of 5 on the MoCA visuospatial/executive test. A Beck Depression Inventory (BDI) score ≤30 was used to indicate the absence of severe depression. HBS: Dementia was defined using operationalized level 1 MDS dementia criteria. These criteria required 1, an MMSE < 26; 2, cognitive deficits severe enough to impact daily living (UPDRS sub-score I item 1, Intellectual impairment score ≥ 2 indicating ‘Dementia has impact on active daily living scale’); 3, impairment in at least two cognitive domains operationalized as impairment in two of the following four tasks: ≤ 3 of 5 points in the MMSE Seven backward test (attention); abnormal clock drawing test (executive dysfunction); subscore = 0 in the MMSE Pentagons (visuo-constructive ability); and ≤ 2 of 3 points in the 3-Word Recall of the MMSE (memory performance). A Geriatric Depression Scale-15 (GDS-15) score <10 was used to indicate the absence of severe depression. 404 individuals European, NR DeNoPa, EPIPARK, HBS